本研究旨在評估一種研究性 RAS(ON) 抑制劑以單藥治療或與化療聯合使用，相較於單獨使用標準治療（SOC）化療的安全性與療效。
適應症：Pancreatic Cancer、Pancreatic Cancer Metastatic、PDAC、PDAC - Pancreatic Ductal Adenocarcinoma、Pancreatic Ductal Adenocarcinoma (PDAC)、Pancreatic Adenocarcinoma Metastatic、Pancreatic Adenocarcinoma、Pancreatic Adenosquamous Carcinoma
收案條件
納入條件
- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed pancreatic adenocarcinoma.
- Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent.
- Documented RAS mutation status, either mutant or wild-type.
- Measurable disease per RECIST v1.1.
- Adequate organ function (bone marrow, liver, kidney, coagulation).
- Able to take oral medications.
排除條件
- Prior treatment with systemic anticancer therapy in metastatic setting or prior RAS-targeted therapy in any treatment setting.
- Active or known history of untreated central nervous system metastatic disease.
- Any conditions that may affect the ability to take or absorb study drug.
- Major surgery within 28 days prior to randomization.
- Patient is unable or unwilling to comply with protocol-required study visits or procedures.
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。